

Jessica J Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1136131/publications.pdf>

Version: 2024-02-01

60
papers

5,186
citations

136885

32
h-index

155592

55
g-index

62
all docs

62
docs citations

62
times ranked

5649
citing authors

#	ARTICLE	IF	CITATIONS
1	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. <i>British Journal of Cancer</i> , 2022, 126, 514-520.	2.9	19
2	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.	0.5	151
3	LTK fusions: A new target emerges in non-small cell lung cancer. <i>Cancer Cell</i> , 2022, 40, 23-25.	7.7	9
4	Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100418.	1.5	29
5	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	3.2	74
6	Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2022, 186, 631-643.	1.9	55
7	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 499-514.	12.5	140
8	Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse. <i>JCO Precision Oncology</i> , 2022, 6, e2100522.	1.5	8
9	Abstract CT545: Variability in <i>NTRK</i> gene fusions does not appear to impact response to larotrectinib. <i>Cancer Research</i> , 2022, 82, CT545-CT545.	0.4	0
10	Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. <i>Nature Cancer</i> , 2022, 3, 710-722.	5.7	28
11	A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100347.	0.6	1
12	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. <i>Clinical Cancer Research</i> , 2021, 27, 1695-1705.	3.2	19
13	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2899-2909.	3.2	62
14	An early look at selective RET inhibitor resistance: new challenges and opportunities. <i>British Journal of Cancer</i> , 2021, 124, 1757-1758.	2.9	6
15	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. <i>Cancer Discovery</i> , 2021, 11, 1913-1922.	7.7	243
16	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. <i>Journal of Thoracic Oncology</i> , 2021, 16, 850-859.	0.5	35
17	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100187.	0.6	11
18	Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. , 2021, 9, e003536.		45

#	ARTICLE	IF	CITATIONS
19	Abstract P224: Update from the Phase 2 registrational trial of repotrectinib in TKI-pretreated patients with <i>ROS1</i> + advanced non-small cell lung cancer and with <i>NTRK</i> + advanced solid tumors (TRIDENT-1). <i>Molecular Cancer Therapeutics</i> , 2021, 20, P224-P224.	1.9	3
20	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 258-265.	0.5	53
21	Imaging Features and Metastatic Patterns of Advanced <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer. <i>American Journal of Roentgenology</i> , 2020, 214, 766-774.	1.0	15
22	Computed Tomography Imaging Features and Distribution of Metastases in <i>ROS1</i> -rearranged Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 153-159.e3.	1.1	20
23	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. <i>Cell</i> , 2020, 183, 347-362.e24.	13.5	349
24	Small cell transformation of <i>ROS1</i> fusion-positive lung cancer resistant to <i>ROS1</i> inhibition. <i>Npj Precision Oncology</i> , 2020, 4, 21.	2.3	36
25	Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with <i>RET</i> Rearrangements. <i>Cancers</i> , 2020, 12, 693.	1.7	16
26	Reply to "Emergence of High Level of <i>MET</i> Amplification During Treatment With Selpercatinib in <i>KIF5B-RET</i> NSCLC". <i>Journal of Thoracic Oncology</i> , 2020, 15, e127-e128.	0.5	1
27	<i>RET</i> Solvent Front Mutations Mediate Acquired Resistance to Selective <i>RET</i> Inhibition in <i>RET</i> -Driven Malignancies. <i>Journal of Thoracic Oncology</i> , 2020, 15, 541-549.	0.5	189
28	<i>MET</i> Alterations Are a Recurring and Actionable Resistance Mechanism in <i>ALK</i> -Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2535-2545.	3.2	127
29	Identification of osimertinib-resistant <i>EGFR</i> L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort. <i>Experimental Hematology and Oncology</i> , 2019, 8, 24.	2.0	14
30	Time to tackle the blood-brain barrier in <i>HER2</i> -mutant lung cancer. <i>Cancer</i> , 2019, 125, 4363-4366.	2.0	3
31	Treatment with Next-Generation <i>ALK</i> Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity. <i>Clinical Cancer Research</i> , 2019, 25, 6662-6670.	3.2	122
32	Efficacy of Alectinib in Patients with <i>ALK</i> -Positive NSCLC and Symptomatic or Large CNS Metastases. <i>Journal of Thoracic Oncology</i> , 2019, 14, 683-690.	0.5	42
33	Molecular Analysis of Plasma From Patients With <i>ROS1</i> -Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 816-824.	0.5	78
34	Refining precision cancer therapy in <i>ALK</i> -positive NSCLC. <i>EBioMedicine</i> , 2019, 41, 9-10.	2.7	1
35	Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 135-140.	0.5	88
36	Sequential <i>ALK</i> Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in <i>ALK</i> -Positive Lung Cancer. <i>Cancer Discovery</i> , 2018, 8, 714-729.	7.7	228

#	ARTICLE	IF	CITATIONS
37	Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 550-558.	0.5	95
38	ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?. <i>Lancet Oncology</i> , The, 2018, 19, 438-439.	5.1	5
39	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	86
40	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	17
41	Impact of <i>EML4-ALK</i> Variant on Resistance Mechanisms and Clinical Outcomes in <i>ALK</i> -Positive Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1199-1206.	0.8	246
42	Antipsychotics and rashes. <i>Mental Illness</i> , 2018, 10, 7808.	0.8	0
43	Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion. <i>Cancer Discovery</i> , 2018, 8, 1529-1539.	7.7	342
44	Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With <i>RET</i> “Rearranged Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1595-1601.	0.5	137
45	Emergence of a <i>RET</i> V804M Gatekeeper Mutation During Treatment With Vandetanib in <i>RET</i> -Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e226-e227.	0.5	43
46	Repotrectinib (TPX-0005) Is a Next-Generation <i>ROS1/TRK/ALK</i> Inhibitor That Potently Inhibits <i>ROS1/TRK/ALK</i> Solvent- Front Mutations. <i>Cancer Discovery</i> , 2018, 8, 1227-1236.	7.7	321
47	Brigatinib in Patients With Alectinib-Refractory <i>ALK</i> -Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1530-1538.	0.5	62
48	Abstract CT043: Highly potent and selective <i>RET</i> inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, <i>RET</i> -altered solid tumors. , 2018, , .		23
49	Abstract CT125: A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad <i>de novo</i> anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer. <i>Cancer Research</i> , 2018, 78, CT125-CT125.	0.4	9
50	<i>ROS1</i> Fusions Rarely Overlap with Other Oncogenic Drivers in Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 872-877.	0.5	87
51	Targeting <i>ALK</i> : Precision Medicine Takes on Drug Resistance. <i>Cancer Discovery</i> , 2017, 7, 137-155.	7.7	405
52	Hypopigmentation in frontal fibrosing alopecia. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1184-1186.	0.6	23
53	Raising the bar on first-line immunotherapy in lung cancer. <i>Lancet Oncology</i> , The, 2017, 18, 2-3.	5.1	4
54	Recent Advances in Targeting <i>ROS1</i> in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1611-1625.	0.5	194

#	ARTICLE	IF	CITATIONS
55	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i> -Positive Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	1.5	158
56	Resisting Resistance: Targeted Therapies in Lung Cancer. <i>Trends in Cancer</i> , 2016, 2, 350-364.	3.8	162
57	Differential Sensitivity to Crizotinib: Does <i>EML4-ALK</i> Fusion Variant Matter?. <i>Journal of Clinical Oncology</i> , 2016, 34, 3363-3365.	0.8	23
58	Clinical Activity of Alectinib in Advanced <i>RET</i> -Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2027-2032.	0.5	85
59	Five-Year Survival in <i>EGFR</i> -Mutant Metastatic Lung Adenocarcinoma Treated with <i>EGFR</i> -TKIs. <i>Journal of Thoracic Oncology</i> , 2016, 11, 556-565.	0.5	268
60	Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer. <i>Cell Reports</i> , 2015, 11, 1549-1563.	2.9	57